MetaCap

Theriva Biologics Inc. (TOVX)

NYSE: TOVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.12-0.008 (-6.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TOVX stock chart

Technical analysis

Key statistics

All statistics
52-week range
0.12 – 0.49
Day range
0.12 – 0.136
Volume / Avg
1.24M / 2.02M
Beta
—

52-week range

$0.12$0.49

TOVX stock today

Theriva Biologics (TOVX) closed at $0.12 on Nov 20, down 6.25% (-$0.008), versus the S&P 500's 3.70% decline. Shares are 75.5% below their 52-week high of $0.49, set on Apr 20, 2026 and 0.0% above the 52-week low of $0.12, near the bottom of the past year's range. TOVX is down 42.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.5%.

Theriva Biologics trades at 0.1x its trailing twelve-month earnings per share of $1.15.

Summary generated from market data by MetaCap's automated system. Methodology

About Theriva Biologics

Company profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Steven A. Shallcross CPA
Headquarters
Rockville, MD
Employees
15

Financial highlights

Full financials

Theriva Biologics reported a net loss of $23.7 million, compared with a loss of $25.7 million a year earlier. Diluted earnings per share came in at -$2.08.

Theriva Biologics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-23.74M$-25.65M$-18.35M$-19.68M$-14.27M
EPS (diluted)$-2.08$-19.03$-28.48$-1.31$-1.90

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$2.50+1983.33%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $1.00High $4.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.03 vs —

TOVX news

All TOVX news

Theriva Biologics peers

Health Care sector
TOVX peer companies
CompanyPrice% ChgMarket capCompare
UPCUniverse Pharmaceuticals Inc. Class A1.08-20.59%$5.43Mvs TOVX
LGVNLongeveron Inc. Class A1.66-8.79%$5.60Mvs TOVX
TPSTTempest Therapeutics Inc.0.287-6.18%$5.74Mvs TOVX
CNSPCNS Pharmaceuticals Inc.3.56-12.75%$5.25Mvs TOVX
SNGXSoligenix Inc.0.2201-8.29%$5.14Mvs TOVX
XCURExicure Inc.0.9001-12.82%$5.89Mvs TOVX
ENVBEnveric Biosciences Inc.1.35-4.26%$6.04Mvs TOVX
ADXNAddex Therapeutics Ltd ADR3.47+2.06%$6.08Mvs TOVX

Indexes, lists and sector

Theriva Biologics stock FAQ

What is Theriva Biologics's stock price today?

TOVX last traded at $0.12 as of Nov 20, 4:00 PM EST, down 6.25% on the day. Prices are delayed at least 15 minutes.

Does Theriva Biologics pay a dividend?

No. Theriva Biologics does not currently pay a regular cash dividend.

What is TOVX's P/E ratio?

TOVX trades at a trailing P/E ratio of 0.10.

Who is Theriva Biologics's CEO?

Mr. Steven A. Shallcross CPA is the chief executive officer of Theriva Biologics Inc., which has about 15 employees.

Has TOVX ever split its stock?

Yes. The most recent TOVX stock split was a 1-for-25 split on Aug 26, 2024, one of 4 splits on record.

What is the TOVX 52-week high?

The 52-week high for TOVX is $0.49 and the 52-week low is $0.12. The stock is currently 75.5% below its high.

Compare TOVX